New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:51 EDTIDRAIdera candidate IMO-8400 likely to be failed drug, says Summer Street
Summer Street predicts Idera Pharmaceuticals' IMO-8400, a small-molecule toll-like receptor antagonist being tested as a treatment for psoriasis, will be a failed drug candidate. The firm says Idera is developing a third-generation product, IMO-9200, which indicates the company has low expectations for IMO-8400.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:31 EDTIDRARBC Capital to hold a conference
Subscribe for More Information
February 17, 2015
09:42 EDTIDRABaker Brothers Advisors buy 5.33M shares of Idera Pharmaceuticals
A filing by Idera Pharmaceuticals director Julian Baker showed that his Baker Bros. Advisors purchased about 5.33M shares of the company's stock in transactions on February 13 at an average price of $3.75 per shares. Idera Pharmaceutical shares are up 6.5% to $4.37 in early trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use